Publications
467 publications
- Date
- Relevance
-
GVS assessment of crisaborole (Staquis®) for the treatment of atopic dermatitis
The National Health Care Institute has completed its assessment whether crisaborole (Staquis®) is interchangeable with a product ...
-
GVS assessment of rivaroxaban (Xarelto®) for the treatment of VTE and prevention of VTE recurrence in children
The National Health Care Institute has completed its assessment whether rivaroxaban (Xarelto®) 1 mg/ml suspension can be included ...
-
Advice on a potential candidate for conditional inclusion of entrectinib (Rozlytrek®) for solid tumours with NTRK gene fusion
Zorginstituut Nederland recommends that entrectinib should be designated as a potential candidate for conditional inclusion. ...
-
Advice on a potential candidate for conditional inclusion of larotrectinib (Vitrakvi®) for solid tumours with NTRK gene fusion
Zorginstituut Nederland recommends that larotrectinib should be designated as a potential candidate for conditional inclusion. ...
-
GVS assessment of 13-valent pneumococcal conjugate vaccine (Prevenar13®) for medical high-risk groups
The National Health Care Institute has completed its assessment whether 13-valent pneumococcal conjugate vaccine (PVC13; ...
-
GVS assessment of Brimonidine Stulln 2mg/ml eye drop solution for decrease of increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
The National Health Care Institute has completed its assessment whether Brimonidine Stulln 2mg/ml eye drop solution, single-use ...
-
GVS assessment of formoterol/ glycopyrronium/ budesonide (Trixeo® aerosphere)
The National Health Care Institute has completed its assessment whether the product formoterol/glycopyrronium/budesonide (Trixeo® ...
-
GVS assessment of sodium zirconium cyclosilicate (Lokelma®) for the treatment of hyperkalemia
The National Health Care Institute has completed its assessment whether sodium zirconium cyclosilicate (Lokelma®) is ...
-
Package advice multiple myeloma
Several combination therapies that are used to treat multiple myelomain are placed in the lock procedure for expensive medicinal ...
-
GVS assessment of opicapone (Ongentys®) for the treatment of Parkinson's disease
The National Health Care Institute has completed its assessment whether opicapone (Ongentys®) is interchangeable with a product ...